STEERLife
STEERLife is the life sciences division of STEER World, licensing proprietary solvent-free continuous processing platforms — FragMelt, Integraal, and PureMelt — to enterprise pharmaceutical companies for the formulation and manufacture of complex, heat- and shear-sensitive drug molecules.
- Company typePrivate
- Founded1992
- HeadquartersBengaluru, India
- Headcount51–100
- GTM typeB2B
- OfferingSoftware
What STEERLife does
STEERLife is the life sciences and pharmaceuticals division of STEER World, a privately held Bangalore-based technology group specializing in twin-screw extrusion and continuous processing. The company develops and licenses proprietary continuous manufacturing platforms for the pharmaceutical industry, focused on solving formulation challenges for heat- and shear-sensitive molecules. Its core platforms are FragMelt™, a solvent-free melt fusion continuous processing technology; Integraal, a continuous granulation system; and PureMelt, a bioavailability-enhancement technology module. Supporting technology modules include Particle Engineering, Partial Fusion, Nano Compounding, and Fractional Geometry technologies, all built on the parent group's compounding and metallurgy expertise.
The company's customers are enterprise pharmaceutical companies. STEERLife operates as a B2B technology licensing partner rather than a drug manufacturer, providing proprietary platforms, application development, and regulatory support to enable partners to develop, validate, and commercialize drug products. Notable commercial milestones include enabling Bionpharma to secure USFDA approval for generic Etravirine tablets (HIV/AIDS treatment) via the FragMelt platform, and a landmark agreement with an undisclosed global pharmaceutical company for the Integraal system covering seven commonly prescribed drugs. Revenue mechanics combine technology licensing/royalties on proprietary platforms with the parent group's broader twin-screw extruder equipment sales (OMega, mEGA, TITAN, aLPHA series) into pharmaceutical, polymer, food, and biomass verticals. The company is led by CEO Indu Bhushan and operates from Bengaluru, India, with global reach via the STEER World parent.
STEERLife firmographics
Firmographics- Name
- STEERLife
- Legal name
- STEERLife
- Website
- https://steerlife.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- STEERLife is the life sciences division of STEER World, licensing proprietary solvent-free continuous processing platforms — FragMelt, Integraal, and PureMelt — to enterprise pharmaceutical companies for the formulation and manufacture of complex, heat- and shear-sensitive drug molecules.
- Ownership category
- akta.pro rank
STEERLife industry classification
Industry- Product category
- Pharmaceutical Manufacturing Technology
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
- akta.pro secondary industries
- Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where STEERLife is headquartered
LocationHeadquarters
- HQ city
- Bengaluru
- HQ country
- India
- HQ region
- Asia
Markets served
STEERLife business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Technology Licensing: STEERLife generates revenue through licensing its proprietary continuous processing platforms (FragMelt, Integraal) to pharmaceutical companies for drug development and manufacturing. The technology enables partners to secure regulatory approvals and commercialize products.
- Equipment Sales: STEER World (parent) sells twin-screw extruders and processing equipment across multiple industry segments including pharmaceuticals, polymers, food, and biomass processing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
STEERLife product offering
Product offeringCore offering
STEERLife develops and licenses proprietary continuous processing platforms for pharmaceutical manufacturing, including the FragMelt solvent-free melt fusion platform and the Integraal Continuous Granulation System. The company enables pharmaceutical manufacturers to formulate heat- and shear-sensitive drug molecules into stable, regulatory-compliant products, with demonstrated USFDA approval for generic Etravirine tablets developed with Bionpharma. Supporting capabilities include bioavailability enhancement (PureMelt), particle engineering, and fractional geometry technologies for controlled drug formulation.
Product overview
STEERLife operates as the life sciences division of STEER World, offering a portfolio of continuous processing technologies for pharmaceutical manufacturing. The core offerings include the FragMelt continuous processing platform (solvent-free melt fusion technology) and the Integraal Continuous Granulation System. Supporting these are specialized technology modules including PureMelt (bio-availability enhancement), Particle Engineering Technology, and Fractional Geometry Technology. The parent company STEER World also manufactures twin-screw extruder equipment (OMega, mEGA, TITAN, aLPHA, ηeti, SAFEReCYCLER Series) and precision components (Screw Elements, Barrels and Liners, Screw Shafts, Vacuum Stuffers, Feeders) primarily for polymers, plastics, food, and nutraceuticals applications. STEERLife's pharmaceutical-focused products enable continuous, solvent-free manufacturing of complex drugs including heat- and shear-sensitive molecules.
Differentiator
Problem solved
Functional benefit
Brands
- FragMelt™: Solvent-free continuous processing platform for pharmaceutical manufacturing, enabling formulation of heat- and shear-sensitive molecules into stable, regulatory-compliant products.
- Integraal
- PureMelt
Products and services
- FragMelt™ Continuous Processing Platform Proprietary solvent-free continuous processing platform that enables formulation of heat- and shear-sensitive drug molecules into stable, regulatory-compliant pharmaceutical products. Licensed to pharmaceutical manufacturers for generic and complex drug formulation.
- Integraal Continuous Granulation System Continuous granulation system designed for streamlined production of uniform, right-sized, high-quality granules, improving efficiency and consistency in pharmaceutical manufacturing. Licensed to pharmaceutical manufacturers.
- OMega Series Twin-screw extruder equipment series for polymer processing applications, part of the STEER World equipment portfolio supporting pharmaceutical and industrial manufacturing.
- mEGA Series Twin-screw extruder equipment series for polymer processing applications, part of the STEER World equipment portfolio supporting pharmaceutical and industrial manufacturing.
- TITAN Series Twin-screw extruder equipment series for polymer processing applications, part of the STEER World equipment portfolio supporting pharmaceutical and industrial manufacturing.
- aLPHA Series Twin-screw extruder equipment series for polymer processing applications, part of the STEER World equipment portfolio supporting pharmaceutical and industrial manufacturing.
- ηeti Series Twin-screw extruder equipment series for polymer processing applications, part of the STEER World equipment portfolio supporting pharmaceutical and industrial manufacturing.
- SAFEReCYCLER Series Twin-screw extruder equipment series designed for safe e-cycling applications in plastic waste solutions, part of the STEER World equipment portfolio.
Quantifiable outcome
- USFDA approval achieved for generic Etravirine tablets developed using FragMelt platform
- +1 more outcomes
Companies that use STEERLife
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
STEERLife technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature10 records
STEERLife partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BionpharmacoreSTEERLife collaborated with Bionpharma to develop generic Etravirine tablets using the proprietary FragMelt continuous processing platform. The partnership enabled Bionpharma to overcome significant technical challenges posed by the drug's extreme sensitivity to heat and shear, resulting in USFDA approval for the HIV/AIDS treatment.
- Global Pharmaceutical Company (undisclosed)coreSTEERLife's Integraal Continuous Granulation System achieved commercial adoption through a landmark agreement with a global pharmaceutical company for development and manufacture of seven commonly prescribed drugs. This represents significant commercial validation of the continuous granulation technology.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
STEERLife competitors and assessment
Company assessmentDirect peers
- GEA Group: Supplies continuous manufacturing equipment and process technology for oral solid dosage forms, including ConsiGma continuous granulation platforms that overlap directly with STEERLife's Integraal offering.
- Glatt Group: Provides integrated process technology for pharmaceutical granulation, coating, and particle engineering — a direct competitor to STEERLife's continuous processing and particle engineering platforms.
- L.B. Bohle: German manufacturer of pharmaceutical processing equipment for granulation, coating, and continuous manufacturing, serving the same pharma customer base with overlapping oral solid dose technology.
Broad incumbents
- IMA Group: Large incumbent in pharma processing and packaging machinery with continuous manufacturing offerings, competing with STEERLife across oral solid dose production lines.
- Syntegon (formerly Bosch Packaging Technology): Major pharma and packaging equipment supplier offering continuous processing solutions alongside broader processing and fill-finish systems that compete with STEERLife's pharma technology portfolio.
- Thermo Fisher Scientific (Patheon): Global CDMO and pharma services giant offering integrated drug development and manufacturing, including continuous processing capabilities that overlap with STEERLife's service scope.
- Catalent: Large CDMO with continuous manufacturing and bioavailability enhancement capabilities, providing an integrated alternative to STEERLife's standalone licensing technology model.
- Lonza: Global CDMO offering small-molecule and biologics manufacturing services including continuous processing investments, competing for complex formulation contracts alongside STEERLife's partners.
Emerging players
- Hovione: CDMO that has invested in proprietary continuous manufacturing capabilities for oral dosage forms, competing for the same complex-generic and bioavailability-enhanced drug projects as STEERLife.
Others
- Lubrizol Life Science: Provides bioavailability-enhancing excipients and drug delivery technologies that address similar solubility and permeability challenges as STEERLife's PureMelt platform, positioning as an alternative solution provider for pharma formulators.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
STEERLife social profiles
Digital presenceSTEERLife financial estimates
Financial estimateRevenue estimate
Valuation estimate
STEERLife leadership team
Management profileNumber of profiles
Profiles1 record
STEERLife funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
STEERLife M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about STEERLife
What does STEERLife do?
STEERLife develops and licenses proprietary continuous processing platforms for pharmaceutical manufacturing, including the FragMelt solvent-free melt fusion platform and the Integraal Continuous Granulation System. The company enables pharmaceutical manufacturers to formulate heat- and shear-sensitive drug molecules into stable, regulatory-compliant products, with demonstrated USFDA approval for generic Etravirine tablets developed with Bionpharma. Supporting capabilities include bioavailability enhancement (PureMelt), particle engineering, and fractional geometry technologies for controlled drug formulation.
Is STEERLife a public or private company?
STEERLife is a private company. It is classified as corporate owned and is currently operating.
When was STEERLife founded?
STEERLife was founded in 1992. It employs 51 to 100 people.
Where is STEERLife based?
STEERLife is headquartered in Bengaluru, India, in the Asia region.
How does STEERLife make money?
Two revenue lines are on record. Technology Licensing is the primary driver. The others are equipment Sales.
Who are STEERLife's main competitors?
Direct peers on record are GEA Group, Glatt Group and L.B. Bohle. Broad incumbents are IMA Group, Syntegon (formerly Bosch Packaging Technology), Thermo Fisher Scientific (Patheon), Catalent and Lonza. Hovione is listed as an emerging player. Lubrizol Life Science is listed as an others.
Does STEERLife have an API?
No public API is recorded for STEERLife.
What industry is STEERLife in?
STEERLife's product category is Pharmaceutical Manufacturing Technology. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 325412 and its SIC code is 2834.